Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 180 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vitamin A palmitate Clear all
Completed Phase 2 Interventional Results available

Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer

NCT00601796
View directory record Official record
Conditions
Lung Cancer
Interventions
Vaccine Treatment, Cyclophosphamide, All-trans retinoic acid (ATRA)
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 22, 2026, 10:57 AM EDT
Completed No phase listed Observational

Vitamins, Breastmilk HIV Shedding, and Child Health

NCT00197756
View directory record Official record
Conditions
Maternal and Child Health Outcomes
Interventions
Vitamin A alone, Multivitamins excluding vitamin A, multivitamins including vitamin A, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older · Female only
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid

NCT00617409
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Paclitaxel, Drug: Ad.p53-DC vaccines, All -trans Retinoic Acid (ATRA)
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome

NCT00002479
View directory record Official record
Conditions
Lymphoma
Interventions
tretinoin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2012 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Retinol on Human Skin Aging in East Asian Descent

NCT02906566
View directory record Official record
Conditions
Intrinsic Aging of Skin
Interventions
Retinol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Open Label Study: Treatment of ALS Fatigue With PolyMVA

NCT04557410
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PolyMVA
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 22, 2026, 10:57 AM EDT
Recruiting Phase 2 Interventional

Essential Amino Acid Supplementation for Femoral Fragility Fractures

NCT06050668
View directory record Official record
Conditions
Femoral Fracture, Fragility Fracture, Muscle Atrophy
Interventions
Essential Amino Acid Supplementation
Combination Product
Lead sponsor
Michael C Willey
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Iowa City, Iowa • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

NCT00866918
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Interventions
Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone Hydrochloride, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
112
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 22, 2026, 10:57 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study

NCT05045703
View directory record Official record
Conditions
Choroideremia
Interventions
Vitamin A palmitate
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
15 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 22, 2026, 10:57 AM EDT
Completed No phase listed Observational

Vitamin Replacement in Abetalipoproteinemia

NCT00004574
View directory record Official record
Conditions
Abetalipoproteinemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

NCT00952523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 22, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Trial of Antibody Responses by Vitamin Supplementation

NCT03859687
View directory record Official record
Conditions
Healthy Participants
Interventions
Vitamin A supplementation, No vitamin A supplementation
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 4 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 22, 2026, 10:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

NCT04700176
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Outcomes After Vitamin A Supplementation in Subjects With SCD

NCT03632876
View directory record Official record
Conditions
Sickle Cell Anemia in Children, Vitamin A Deficiency in Children
Interventions
retinyl palmitate
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
9 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles

NCT01283464
View directory record Official record
Conditions
Photodamaged Skin, Wrinkles
Interventions
Retinol, Tretinoin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
35 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

NCT03427554
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rejuvant™ Safety and Biomarker Study

NCT04821401
View directory record Official record
Conditions
Aging Well
Interventions
Rejuvant, Placebo
Dietary Supplement
Lead sponsor
Ponce De Leon Health
Industry
Eligibility
45 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Results available

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

NCT00346333
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Lutein, Cornstarch control
Drug · Dietary Supplement
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

NCT01404949
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
Tretinoin and Arsenic Trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Evanston, Illinois • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo

NCT01135069
View directory record Official record
Conditions
Acne
Interventions
Tretinoin microsphere 0.1%, Brand Retin-A Micro tretinoin microsphere gel 0.1%, placebo microsphere gel
Drug
Lead sponsor
Spear Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Phase II 5-Azacytidine Plus VPA Plus ATRA

NCT00326170
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Interventions
5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 22, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

NCT01208454
View directory record Official record
Conditions
Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Isotretinoin, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 22, 2026, 10:57 AM EDT
Not listed Phase 4 Interventional

Efficacy & Safety of Clindamycin and Tretinoin in Acne

NCT01111994
View directory record Official record
Conditions
Acne
Interventions
Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
Drug
Lead sponsor
Callender Center for Clinical Research
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Mitchellville, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2010 · Synced Sep 22, 2026, 10:57 AM EDT